Major Depressive Disorder

Ketamine-assisted psychotherapy has transformative potential as a groundbreaking approach to mental health that enhances healing through psychedelic experiences.

Seaport Therapeutics initiates a pivotal study for GlyphAllo, a potential breakthrough treatment for major depressive disorder, with or without anxious stress.

A groundbreaking study reveals that reduced cortical thickness in the parahippocampus may indicate major depressive disorder and neuroticism traits.

Yvette Elpidio, PMHNP-BC, shares insights on NMDA agonists at the Southern California Psychiatry conference.

Fava beans emerge as a powerful natural source of L-DOPA, offering potential benefits for mood disorders and Parkinson's disease and holding enriching culinary traditions.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

Researchers analyze single-cell communication in brains of people with PTSD, uncovering genetic variations that could lead to new treatments for this complex disorder.

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

New research reveals how ezogabine targets potassium channels in the brain, offering innovative treatment options for major depressive disorder symptoms.

Alto Neuroscience's ALTO-203 trial reveals mixed results, highlighting potential biomarkers for targeted depression treatment despite missing primary efficacy goals.

Researchers uncover a novel biomarker for major depressive disorder, linking regional homogeneity in fMRI to decreased cerebral blood flow and symptom severity.

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

There is a critical link between sleep disorders and psychiatric conditions. In this Special Report, examine effective diagnosis and treatment strategies for better patient outcomes.

Daniel Morehead, MD, critiques the discourse around antidepressants, urging a balanced view of their benefits and risks while addressing patient concerns.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

In this CME article, learn more about the essential role of MAOIs in treating resistant depression and anxiety.

Cariprazine shows promise as a long-term adjunctive treatment for anhedonia in major depressive disorder, according to new poster data presented at the ASCP Annual Meeting.

Poster presented at the APA Annual Meeting finds zuranolone effective for anhedonia associated with PPD.

What is the hidden mental health struggles of affluent youth? In this Tales From the Clinic article, we reveal how wealth can contribute to anxiety, depression, and substance misuse.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

NRx Pharmaceuticals secures FDA fee waiver for NRX-100, a preservative-free ketamine aimed at treating suicidal depression, enhancing accessibility for patients.

Check out the pipeline updates from April!

Discover how deep brain stimulation, a breakthrough treatment, offers hope for patients with treatment-resistant depression.

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

Patients with treatment resistant late-life depression are more likely to respond to antidepressants when sleep is sufficient or has improved.